Ser23
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser23  -  UNG (human)

Site Information
ARKRHAPsPEPAVQG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2018600

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 34 ) , mass spectrometry ( 1 , 2 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 15 , 16 , 17 , 18 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 ) , mutation of modification site ( 34 ) , western blotting ( 34 )
Disease tissue studied:
breast cancer ( 4 , 8 , 9 ) , breast ductal carcinoma ( 8 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 , 8 ) , cervical cancer ( 28 ) , cervical adenocarcinoma ( 28 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 16 ) , acute megakaryoblastic leukemia (M7) ( 16 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 16 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 16 ) , acute myeloblastic leukemia, without maturation (M1) ( 16 ) , lung cancer ( 12 , 17 , 21 , 22 ) , non-small cell lung cancer ( 17 ) , non-small cell lung adenocarcinoma ( 12 , 21 ) , lymphoma ( 10 ) , B cell lymphoma ( 16 ) , Burkitt's lymphoma ( 10 ) , non-Hodgkin's lymphoma ( 16 ) , follicular lymphoma ( 10 ) , mantle cell lymphoma ( 10 ) , ovarian cancer ( 8 ) , multiple myeloma ( 16 ) , melanoma skin cancer ( 6 )
Relevant cell line - cell type - tissue:
293 (epithelial) [AT1 (human), transfection] ( 27 ) , 293 (epithelial) ( 29 ) , A549 (pulmonary) ( 22 ) , AML-193 (monocyte) ( 16 ) , breast ( 2 , 8 ) , Calu 6 (pulmonary) ( 17 ) , CMK (megakaryoblast) ( 16 ) , CTS (myeloid) ( 16 ) , DG75 (B lymphocyte) ( 26 ) , DOHH2 ('B lymphocyte, precursor') ( 16 ) , FL-18 (B lymphocyte) ( 10 ) , FL-318 (B lymphocyte) ( 10 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 18 ) , Flp-In T-Rex-293 (epithelial) ( 18 ) , H2009 (pulmonary) ( 17 ) , H2077 (pulmonary) ( 17 ) , H2887 (pulmonary) ( 17 ) , H322M (pulmonary) ( 17 ) , HEK293T (epithelial) ( 5 ) , HEL (erythroid) ( 16 ) , HeLa (cervical) ( 1 , 7 , 15 , 20 , 24 , 32 , 33 , 34 ) , HeLa S3 (cervical) ( 28 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 9 ) , HMLER ('stem, breast cancer') ( 9 ) , HUES-9 ('stem, embryonic') ( 23 ) , Jurkat (T lymphocyte) ( 13 , 25 , 31 ) , K562 (erythroid) ( 15 ) , Kasumi-1 (myeloid) ( 16 ) , KG-1 (myeloid) ( 16 ) , lung ( 12 ) , MCF-7 (breast cell) ( 4 ) , MV4-11 (macrophage) ( 16 ) , NCEB-1 (B lymphocyte) ( 10 ) , NCI-H1395 (pulmonary) ( 17 ) , NCI-H157 (pulmonary) ( 17 ) , NCI-H1648 (pulmonary) ( 17 ) , NCI-H1666 (pulmonary) ( 17 ) , NCI-H2030 (pulmonary) ( 17 ) , OPM-2 (plasma cell) ( 16 ) , ovary ( 8 ) , P31/FUJ (erythroid) ( 16 ) , Raji (B lymphocyte) ( 10 ) , RAMOS (B lymphocyte) ( 10 ) , REC-1 (B lymphocyte) ( 10 ) , RL ('B lymphocyte, precursor') ( 16 ) , RPMI-8266 (plasma cell) ( 16 ) , SH-SY5Y (neural crest) ( 11 ) , SU-DHL-4 (B lymphocyte) ( 10 ) , SU-DHL-6 (B lymphocyte) ( 16 ) , U-1810 (pulmonary) [EFNB3 (human), knockdown] ( 21 ) , U-1810 (pulmonary) ( 21 ) , U266 (plasma cell) ( 16 ) , UPN-1 (B lymphocyte) ( 10 ) , WM115 (melanocyte) ( 30 ) , WM239A (melanocyte) ( 6 )

Upstream Regulation
Kinases, in vitro:
CDK2 (human) ( 34 )
Treatments:
anti-CD3 ( 31 ) , EGF ( 1 )

Downstream Regulation
Effects of modification on UNG:
activity, induced ( 34 ) , enzymatic activity, induced ( 34 ) , molecular association, regulation ( 34 )
Induce interaction with:
DNA ( 34 ) , RPA1 (human) ( 34 )

References 

1

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

4

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

5

Franchin C, et al. (2015) Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells. Biochim Biophys Acta 1854, 609-23
25278378   Curated Info

6

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

7

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

8

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

9

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

10

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

11

Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76
24117733   Curated Info

12

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

13

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

14

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

15

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

16

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

17

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

18

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

19

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

20

Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540
21857030   Curated Info

21

Ståhl S, et al. (2011) Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor. J Proteome Res 10, 2566-78
21413766   Curated Info

22

Yu G, et al. (2011) Phosphoproteome profile of human lung cancer cell line A549. Mol Biosyst 7, 472-9
21060948   Curated Info

23

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

24

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

25

Possemato A (2010) CST Curation Set: 10874; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

26

Iliuk AB, et al. (2010) In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers. Mol Cell Proteomics 9, 2162-72
20562096   Curated Info

27

Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304
20686112   Curated Info

28

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

29

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

30

Old WM, et al. (2009) Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell 34, 115-31
19362540   Curated Info

31

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

32

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

33

Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50
18452278   Curated Info

34

Hagen L, et al. (2008) Cell cycle-specific UNG2 phosphorylations regulate protein turnover, activity and association with RPA. EMBO J 27, 51-61
18079698   Curated Info